Annals of Oncology

abstracts
Legal entity responsible for the study: N/A
Funding: Antwerp University Hospital- UZA - Oncology Department
Disclosure: All authors have declared no conflicts of interest.
55PD
Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF
mutated cancers: first results of the ACSE trial
J-Y. Blay 1 , J. Mazieres 2 , D. Perol 3 , F. Barlesi 4 , D. Moro-Sibilot 5 , G. Quere 6 ,
J. Tredaniel 7 , X. Troussard 8 , S. Leboulleux 9 , D. Malka 10 , A. Flechon 1 ,
C. Linassier 11 , I.L. Ray-Coquard 12 , B. Arnulf 13 , I. Bieche 14 , G. Ferretti 15 ,
F. Nowak 16 , M. Jimenez 17 , N. Hoog-Labouret 16 , A. Buzyn 16
1 Medical Oncology, Centre Léon Bérard, Lyon, France, 2 Thoracic Oncology, CHU
Toulouse, Hôpital de Larrey, Toulouse, France, 3 Direction de la Recherche Clinique
et de l’Innovation, Centre Léon Bérard, Lyon, France, 4 Multidisciplinary Oncology
& Therapeutic Innovation, Hopital Nord, Marseille, France, 5 Thoracic Oncology,
CHU Grenoble - Hopital Michallon, La Tronche, France, 6 ICH, C.H.U. Brest -
Hôpital Morvan, Brest, France, 7 Service de Pneumologie, Hopital St. Joseph,
Paris, France, 8 Service of Hematology, CHU de Caen, Caen, France, 9 Nuclear
Medicine and Endocrine Oncology, Institut de Cancérologie Gustave Roussy,
Villejuif, France, 10 Digestive Oncology, Institut de Cancérologie Gustave Roussy,
Villejuif, France, 11 Medical Oncology, CHRU Bretonneau, Tours, France,
12 Medecine, Centre Léon Bérard, Lyon, France, 13 Medical Oncology, Hôpital
St. Louis, Paris, France, 14 Pharmacogenomic, Institut Curie, Paris, France,
15 Radiology, CHU Grenoble - Hopital Michallon, La Tronche, France, 16 Research
and Innovation, Institut National du Cancer, Boulogne-Billancourt, France, 17 R&D,
Unicancer, Paris, France
Background: BRAF mutations (mut) are observed in several cancer histotypes at low
frequency (